NK NantKwest Inc.

1.22
+0.1  (+9%)
Previous Close 1.12
Open 1.12
Price To Book 0.72
Market Cap 120,382,467
Shares 98,674,153
Volume 165,948
Short Ratio
Av. Daily Volume 397,707

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
Phase 1/2 ongoing.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
First dosing announced October, 2017.
haNK
Solid tumors
Phase 2 ongoing.
aNK
Merkel cell carcinoma
Phase 2 initiation announced January 9, 2018.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)
Phase 1b abstract at ASCO noted 2/8 SAEs.
haNK + other vaccines (NANT vaccine) (ASCO 2019)
Triple Negative Breast Cancer
IND clearance announced June 5, 2019.
CD19-t-haNK
B-cell lymphoma
Phase 1b data at ASCO 2019 - ORR of 58%, CR rate of 33%.
Nanatinostat (VRx-3996) and valganciclovir
Epstein-Barr Virus Associated Lymphoma
Phase 1 trial to be initiated.
PD-L1 t-haNK
Solid tumors

Latest News

  1. Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?
  2. NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
  3. Cheryl Cohen Appointed to NantKwest’s Board of Directors
  4. NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
  5. NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
  6. NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
  7. NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
  8. NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
  9. What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?
  10. Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
  11. NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
  12. Will NantKwest Continue to Surge Higher?
  13. NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
  14. NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
  15. NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
  16. Our Take On NantKwest, Inc.’s (NASDAQ:NK) CEO Salary
  17. Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
  18. NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
  19. Soon-Shiong’s NantCell gets $30 million from Celgene
  20. NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs